前列腺筛查试验中初次良性前列腺穿刺活检男性的长期结局:一项基于人群的队列研究
本研究纳入哥德堡前列腺癌筛查试验第一轮筛查中初次前列腺活检为良性的452名男性,随访中位21.1年。20年累积前列腺癌发病率为40.0%,前列腺癌死亡率为1.4%;初次PSA≤10ng/ml者分别为38.8%和0.6%,PSA>10ng/ml者分别为64.4%和21.4%。作者认为参与筛查项目者死于前列腺癌风险很低,但长期随访中许多男性会被诊断并治疗前列腺癌。
要点
- 初次良性前列腺活检后20年累积前列腺癌发病率为40.0%,前列腺癌死亡率为1.4%。
- 初次PSA≤10ng/ml者20年累积发病率为38.8%、死亡率为0.6%。
- 初次PSA>10ng/ml者20年累积发病率为64.4%、死亡率为21.4%。
核心结论
- 初次前列腺活检为良性的男性参与筛查项目时死于前列腺癌的风险很低。
- 但长期随访中许多男性会被诊断并治疗前列腺癌。
- 作者认为对于良性活检后PSA≤10ng/ml的男性,哥德堡试验中的低强度随访似乎足够。
研究设计与样本
- 基于人群的队列研究,纳入哥德堡前列腺癌筛查试验第一轮筛查中所有初次活检为良性的男性。
- 随访期为1995年1月1日至2017年5月15日,共452名男性,中位随访21.1年。
- 干预为每两年进行一次前列腺特异性抗原(PSA)检测(年龄上限中位数为69岁),PSA≥3ng/ml者接受前列腺活检(2009年前为六点活检)。
主要发现
- 452名男性中169例被诊断为前列腺癌,5例死于前列腺癌。
- 20年累积前列腺癌发病率为40.0%,前列腺癌死亡率为1.4%。
- 初次PSA≤10ng/ml男性20年累积发病率为38.8%、死亡率为0.6%;PSA>10ng/ml男性分别为64.4%和21.4%。
- 末次随访时未治疗比例在两个PSA组相似(22% vs 23%)。
临床怎么用
- 作者认为,对于初次良性活检后PSA≤10ng/ml的男性,低强度随访(如哥德堡试验中所用)似乎足够。
局限性
- 试验多年使用六点活检是一项局限性。
- 原文报告随访中位21.1年,未提及其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal follow-up regimen for men after a benign prostate biopsy remains unknown. OBJECTIVE: To investigate long-term outcomes for men after an initial benign prostate biopsy. DESIGN, SETTING, AND PARTICIPANTS: All men with a benign biopsy in the first screening round of the Göteborg prostate cancer (PC) screening trial were included. The follow-up period was January 1, 1995-May 15, 2017. INTERVENTION: Prostate-specific antigen (PSA) tests were performed every second year (upper median age limit 69yr). Men with PSA ≥3ng/ml underwent prostate biopsy (sextant biopsy up to 2009). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The 20-yr cumulative PC incidence and PC mortality were calculated using the 1 minus Kaplan-Meier method. RESULTS AND LIMITATIONS: Of 452 men with a benign biopsy and followed for a median of 21.1yr, 169 were diagnosed with PC and five died from PC. The 20-yr cumulative PC incidence and PC mortality were 40.0% and 1.4%, respectively. The corresponding figures were 38.8% and 0.6% for men with initial PSA ≤10ng/ml, and 64.4% and 21.4% for PSA >10ng/ml. The proportion of men untreated at final follow-up was similar in the two PSA groups (22% vs 23%). The use of sextant biopsy for many years of the trial is a limitation. CONCLUSIONS: Men with an initial benign prostate biopsy run a very low risk of dying from PC when participating in a screening program. However, if followed for a long period, many men will be diagnosed and treated for PC. Low-intensity follow-up, as in the Göteborg trial, appears sufficient for men with PSA ≤10ng/ml after a benign biopsy. PATIENT SUMMARY: This study shows that men who participate in a prostate cancer screening trial have a low risk of dying from prostate cancer if the first biopsy does not show cancer.
引用
- Palmstedt E, Månsson M, Frånlund M, et al. Long-term Outcomes for Men in a Prostate Screening Trial with an Initial Benign Prostate Biopsy: A Population-based Cohort. Eur Urol Oncol. 2019. PMID: 31411967. doi:10.1016/j.euo.2019.01.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。